Sign In
Buy NPCE
$15.88
-0.410 (-2.52%)
At Close: Jun 03, 2026
NeuroPace, Inc. (NASDAQ:NPCE) Receives Average Recommendation of “Moderate Buy” from Brokerages
04:44am, Tuesday, 10'th Feb 2026
Shares of NeuroPace, Inc. (NASDAQ: NPCE - Get Free Report) have received an average rating of "Moderate Buy" from the eight ratings firms that are covering the stock, Marketbeat.com reports. One inves
NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
07:46pm, Wednesday, 14'th Jan 2026
NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
07:30am, Tuesday, 13'th Jan 2026
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported preliminary unaudited
NeuroPace (NASDAQ:NPCE) and Envoy Medical (NASDAQ:COCH) Critical Comparison
01:10am, Monday, 12'th Jan 2026
NeuroPace (NASDAQ: NPCE - Get Free Report) and Envoy Medical (NASDAQ: COCH - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two compa
NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference
09:00am, Wednesday, 31'st Dec 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management t
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy
08:00am, Wednesday, 17'th Dec 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that it has filed a P
NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy
08:00am, Monday, 08'th Dec 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, announced the presentation at the Ame
Baird Medical Appoints Mark Saxton as U.S. CEO; Taps Veteran from NeuroPace, Smith + Nephew, and Covidien to Lead Commercial Expansion
08:30am, Wednesday, 03'rd Dec 2025
NEW YORK , Dec. 3, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technol
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its RNS System a
NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services
08:00am, Monday, 24'th Nov 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today announced favorable Medicar
Y Intercept Hong Kong Ltd Takes Position in NeuroPace, Inc. $NPCE
03:40am, Thursday, 06'th Nov 2025
Y Intercept Hong Kong Ltd bought a new stake in shares of NeuroPace, Inc. (NASDAQ: NPCE) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission
NeuroPace, Inc. (NPCE) Q3 2025 Earnings Call Transcript
11:06pm, Tuesday, 04'th Nov 2025
NeuroPace, Inc. ( NPCE ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Scott Scaper Joel Becker - CEO, President & Director Patrick Williams - Chief Financial Officer Confere
NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates
07:21pm, Tuesday, 04'th Nov 2025
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.19 per share a year ago.
NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
04:05pm, Tuesday, 04'th Nov 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for
NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025
08:00am, Wednesday, 22'nd Oct 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financ
